29,008 Shares in Sanofi $SNY Purchased by Strategic Investment Advisors MI

Strategic Investment Advisors MI acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the 1st quarter, Holdings Channel reports. The fund acquired 29,008 shares of the company’s stock, valued at approximately $1,398,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Arkadios Wealth Advisors grew its holdings in shares of Sanofi by 0.9% during the first quarter. Arkadios Wealth Advisors now owns 36,146 shares of the company’s stock valued at $1,742,000 after buying an additional 315 shares during the last quarter. IFS Group LLC purchased a new stake in Sanofi during the 1st quarter valued at $322,000. ADAR1 Capital Management LLC increased its holdings in shares of Sanofi by 399.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 316,939 shares of the company’s stock worth $15,270,000 after purchasing an additional 253,465 shares in the last quarter. Guardian Partners Inc. raised its stake in shares of Sanofi by 0.5% in the first quarter. Guardian Partners Inc. now owns 204,086 shares of the company’s stock worth $9,860,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Amundi bought a new position in shares of Sanofi during the first quarter valued at $525,000. Institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent analyst reports. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Monday, April 20th. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research report on Wednesday, July 8th. Citigroup restated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Finally, Argus raised Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Sanofi has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Trading Down 1.5%

Sanofi stock opened at $44.85 on Thursday. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The firm has a market capitalization of $108.74 billion, a price-to-earnings ratio of 12.53, a P/E/G ratio of 1.15 and a beta of 0.34. The firm has a 50 day moving average of $43.50 and a 200 day moving average of $45.27. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.